Cite
810-5 Use of either metformin or thiazolidinedione is associated with improved survival among patients with type 2 diabetes from a registry of 16,203 diabetic patients.
MLA
Lavasani, Farangis, et al. “810-5 Use of Either Metformin or Thiazolidinedione Is Associated with Improved Survival among Patients with Type 2 Diabetes from a Registry of 16,203 Diabetic Patients.” Journal of the American College of Cardiology (JACC), vol. 43, Mar. 2004, p. A474. EBSCOhost, https://doi.org/10.1016/S0735-1097(04)92007-4.
APA
Lavasani, F., Muhlestein, J. B., Einhorn, D., Pearson, R. R., Jones, H. U., Horne, B. D., Bair, T. L., Thomas, H., Renlund, D. G., Lappe, D. L., & Anderson, J. L. (2004). 810-5 Use of either metformin or thiazolidinedione is associated with improved survival among patients with type 2 diabetes from a registry of 16,203 diabetic patients. Journal of the American College of Cardiology (JACC), 43, A474. https://doi.org/10.1016/S0735-1097(04)92007-4
Chicago
Lavasani, Farangis, Joseph B Muhlestein, Dalton Einhorn, Robert R Pearson, Heath U Jones, Benjamin D Horne, Tami L Bair, et al. 2004. “810-5 Use of Either Metformin or Thiazolidinedione Is Associated with Improved Survival among Patients with Type 2 Diabetes from a Registry of 16,203 Diabetic Patients.” Journal of the American College of Cardiology (JACC) 43 (March): A474. doi:10.1016/S0735-1097(04)92007-4.